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INTRODUCTION: 
Bipolar Affective Disorder: Bipolar disorder (also 
known as manic depression) causes serious shifts in 
mood, energy, thinking, and behavior from the highs of 
mania on one extreme, to the lows of depression on the 
other1. It is a medical complex- illness and also known as 
manic depression disorders2. The term "manic–
depressive illness" or psychosis was coined by German 
psychiatrist Emil Kraepelin in the late nineteenth 
century, originally referring to all kinds of mood 
disorder. But , German psychiatrist Karl Leonhard split 
the classification in 1957, employing the terms unipolar 
disorder (major depressive disorder) and bipolar 
disorder3 . 
Hypothyroidism: Hypothyroidism, it is commonly 
characterised by abnormal production of thyroid 
hormones. Thyroid hormone mainly acts as a 
neurotransmitter. The imbalance in thyroid hormones 
mainly mimics or shows similar symptoms that are 
associated with psychiatric disease4 .  The symptoms 
associated with hypothyroidism are fatigue, depression, 
cold intolerance and excessive sleepiness etc. 
Many studies suggest that the hypothyroidism is a most 
commonly found abnormality in bipolar affective 
disorder. Some studies also suggest that lithium-
treatment has a potential to exacerbate a preexisting 
hypothyroid state or to induce hypothyroidism. 
CASE REPORT: 
A 44 yrs old man was admitted to Malla Reddy medical 
college hospital and research center, Suraram with chief 
complaints of fatigue, depression and cold intolerance 
since 1 week. This patient was a known case bipolar 
affective disorder which was previously diagnosed and 
treated in NIMS 2013. He is an employee in 
manufacturing industry for past 7 years. He is on 
following treatment with Tab.  Lithium-300mg BID, 
Tab. Clozapine-30mg/day, Tab. Haloperidol-10mg/day 
and in social history he is alcoholic and smoker.
 
Lab Investigations: 
Blood Sugar (mg%) Day1 Day2          
Blood Sugar Fasting(70-110) 80 N         
Blood Sugar Post Lunch(70-150) 110 N         
Blood Sugar Random(80-120) 90 N         
 
 
 
 
 
 
ABSTRACT: 
Bipolar affective disorder along with hypothyroidism is well documented. There are few studies regarding hypothyroidism in 
patients with bipolar affective disorder. Here our main motto is to report such a case who was presented with bipolar affective 
disorder along with hypothyroidism as a co-morbidity & to provide a brief information regarding association of 
hypothyroidism in bipolar affective disorder. Treatment approaches in such co-morbid conditions. 
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Complete Blood Picture  Liver Function Test 
Hb(g/dl) (M-11-16 F-11-14) :   12 
RBC(millcells/cumm)(4-6.5) : 4.6 
 WBC(cells/cumm)(4000-11000) : 7,500 
Differential Leukocyte Count 
Neutrophils(40-75%) : 65% 
Lymphocytes(20-45%) : 30% 
Eosinophils(01-06) : 5% 
Monocytes(02-10%) :2% 
Basophils(upto 1) : 
Platelet Count(1.5-4.5lakhs/cumm) : Adequate 
Peripheral Smear 
RBCs : 
WBCs : 
Serum Bilirubin Total(upto 1mg/dl) : 0.7 
Direct (upto 0.25mg/dl) : N 
Indirect : 
SGPT (upto 65 IU/L) : 44 
SGOT (upto 37 IU/L) :33 
Alkaline Phosphatase(15-116 IU/L) : 110 
Total Proteins (6-8gm/dl) : 7 
Albumin (3.2-5.8gm/dl) : N 
Globulin (2.2-4.8gm/dl) : N 
Lipid Profile (mg/dl) 
Total Cholesterol (140-250) : 220 
HDL Cholesterol (30-65) : 45 
LDL Cholesterol (80-180) : 90 
VLDL Cholesterol (5-45) : 35 
Triglycerides (25-160) : 140 
TC/HDL Ratio (upto 4.5) : N 
ESR (M-0-10mm/hr F-0-20mm/hr) :  
Urine Analysis 
Color : 
Appearance : 
Pus Cells : 
Albumin : 
Epithelial Cells : 
Glucose : 
RBC : 
Biochemical Investigations (mg/dl) 
Serum Creatinine (0.6-1.4) : 1.2 
Blood Urea (14-45) : 40 
Serum Electrolytes (mmols/L) 
Serum Sodium(135-155) : 140 
Serum Potassium (3.6-5.5) : 4.2 
Serum Chlorides (98-108) : N 
Serum Phosphates (2.5-5)) : N 
Serum  Calcium (8-10.8) : N 
Thyroid Functions Test 
T3 (60-181 ng/dl) :  35 ng/dl-- DECREASED 
T4 (7.3-15μg/dl) :   4.3 μg/dl-- DECREASED 
TSH (0.55-4.78μIU/L) : 6.7---INCREASED 
 
 
DISCUSSION; 
Bipolar affective disorder is a complex medical illness. It 
is mainly characterised by serious shifts in mood, energy, 
thinking, and behavior—from the highs of mania on one 
extreme, to the lows of depression on the other. In this 
present case, the patient had a past history of bipolar 
affective disorder, admitted and treated in NIMS 
hospital. He is on following treatment with Tab.  
Lithium-300mg BID, Tab. Clozapine-30mg/day, Tab. 
Haloperidol-10mg/day. 
Currently, the patient was admitted in the hospital with 
chief complaints of fatigue, depression and cold 
intolerance since 1 week. Inspite of use of antidepressant 
drugs the patient’s bipolar affective disorder symptoms 
were not controlled. When the patient blood parameters 
were investigated, it was founded that there was a 
decrease in T3, T4 and increase in TSH levels. With the 
subjective (symptoms) and objective (lab investigation) 
the patient has diagnose with hypothyroidism. Here in 
this présent case, the main etiological factor for 
hypothyroidism is use of lithium (an antipsychotic drug 
used for treating bipolar affective disorder). 
The  mechanism with which lithium induces 
hypothyroidism or excerbate the hypothyroidism  is 
complex5. Lithium gets concentrâtes in the thyroid gland 
and inhibits thyroidal iodine uptake.It also inhibits 
iodotyrosine coupling , alter thyrolobulin structure, 
inhibits thyroid hormones excretion and interferes with 
the deiodination of T4 to T3 by inhibiting type -II 
deiodinase in the brain. Johnston and Eagles found a 
10.4% prevalence of clinical hypothyroidism in patients 
who are on lithium therapy6.  
Kupka et al. found thyroperoxidase antibodies in 64 of 
226 (28%) outpatients with bipolar disorder, 7 a rate 
higher than general population subjects. Although, 
lithium is most effective in treating bipolar affective 
disorder,  it has potential to cause hypothyroidism by the 
above stated mechanism. Because lithium has ability to 
cause hypothyroidism, the patient thyroid profile should 
be carefully examined before initiating lithium therapy 
and if patient found to be hypothyroid than thyroid 
supplementation should be initiated. 
Some studies suggest that the patients with bipolar 
disorder, supraphysiological doses of T4 is mainly 
usefull as a supplement for prophylactic efficacy of 
mood stabilizing agents. It is also use to augment the 
antidepressant  treatment.  
Bauer and Whybrow conducted the ﬁrst open label trial 
of adjunctive supraphysiologicaldoses of T4 in 11 
patients with treatment-refractory bipolar affective 
disorder8. Adjunctive treatment withT4 reduced the 
severity of manic and the depressive phases in both 
amplitude and frequency,and even led to complete 
remission in some patients. Thyroxine was used in doses 
of 250–500 mcg/day in these studies, the goal was to 
achieve TSH suppression by increasing free T4 levels by 
Reddy et al                                     Journal of Drug Delivery & Therapeutics; 2014, 4(2), 99-101 101 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
>50% of pretreatment levels. Despite concerns about 
adverse eﬀects, 9  the treatment was rated favourably by 
recipients and was well tolerated10 . 
Two of the more recent studies have attempted thyroid 
hormone augmentation of patients with refractory bipolar 
depression using slightly diﬀerent strategies. Łojko et al. 
found addition of moderate doses of T 4 (100 mcg/day) 
to be a successful augmentation strategy in female 
patients with bipolar depression, who had  an 
unsatisfactory response to serotonergic antidepressants11.  
Another retrospective chart review of 125 patients with 
treatment resistant bipolar depression showed 
augmentation with high dose T3 to be highly eﬀective12. 
In this present case, augmentation with thyroxine at a 
intial dose of 50–100 mcg/day and increased by 25–50 
mcg per week, to a maximum of 500 mcg per day 
showed a dramatic improvement in bipolar affective 
disorder symptoms and patient thyroid profile. 
CONCLUSION; 
According to our study we conclude that the lithium 
treatment has a potential to exacerbate a preexisting 
hypothyroid state or to induce hypothyroidism. Because 
lithium has ability to cause hypothyroidism, the patient 
thyroid profile should be carefully examined before 
initiating lithium therapy and if patient found to be 
hypothyroid than thyroid supplementation should be 
initiated. Several studies suggest that the use of 
supraphysiological doses of thyroxine in patients with 
bipolar affective disorder showed better improvement in 
symptoms. So, attention should be showed on the thyroid 
profile of the patient with bipolar affective disorder and 
thyroxine augmentation should be done based on 
patient’s thyroid profile. Special precautions are required 
in those with endocrine or cardiovascular disorders. 
Administration during pregnancy is not recommended. 
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